Nugent wins Victoria Prize
18 August, 2004 by Melissa TrudingerThe Victoria Prize was awarded today to Melbourne University physicist Prof Keith Nugent for his work on phase imaging and X-ray optics.
Expressions of interest sought for trade mission to UK
17 August, 2004 by Melissa TrudingerExpressions of interest are being sought from Australian biotechnology companies interested in joining a trade mission to the United Kingdom and BioPartnering Europe 2004.
TasInformatics ready for take-off
16 August, 2004 by Melissa TrudingerThe AUD$20 million flagship project of Tasmania's Intelligent Island initiative funded by the Australian Government and jointly managed with the state government -- the Tasinformatics Centre of Excellence at the University of Tasmania -- is due to get off the ground in the coming weeks, once final negotiations between the university and the state government have been completed.
Chemeq calls trading halt, appeals for more capital
16 August, 2004 by Melissa TrudingerChemeq (ASX: CMQ) has called a trading halt while it considers a proposal to raise equity funds to use as working capital and to expand its current production facility from 20 tonnes annual production capacity to 50 tonnes.
Origin Capital's $6.5 million biotech play
16 August, 2004 by Melissa TrudingerOrigin Capital, an unlisted pooled development fund set up by TSL Group's Ross Dobinson and Michael Naphtali, has raised AUD$6.5 million in private equity for investment into three biotech ventures.
Early-stage funding is out there for those who deserve it
16 August, 2004 by Melissa TrudingerThe early stage funding is out there, but would-be biotech companies need to demonstrate quality to get the cash, according to the people who hold the seed-funding purse strings.
NZ to kick in $5 million for Synchrotron
13 August, 2004 by Melissa TrudingerNew Zealand will provide AUD$5 million towards the synchrotron beamlines, pushing beamline funding over $25 million - half of the $49 million required to set up the initial suite of beamlines.
Epitan raises $8 million in private placement
11 August, 2004 by Renate KrelleEpiTan (ASX: EPT) has raised AUD$7.98 million via a private placement of 10.5 million fully paid ordinary with two European investors.
'Just add water' works for BTF
09 August, 2004 by Renate KrelleThere must be something in the water in Sydney’s North Ryde that encourages biotech.
CSIRO’s IP revenues on the up
05 August, 2004 by Graeme O'NeillCSIRO has reported sharp rise in intellectual property revenues 2003-04 financial year, to $22 million -- a 60 per cent increase on its 2003-03 figure of $13.75 million.
Circadian boasts $5.8m profit
02 August, 2004 by Melissa TrudingerCircadian Technologies (ASX:CIR) has posted a AUD$5.8 million profit for the 2003-04 financial year, and the prospects of an even better year next year thanks to the recent acquisition of its investee company Axon Instruments by US firm Molecular Devices on July 1.
Revenir raises $1.5 million, expects oversubscription
28 July, 2004 by Melissa TrudingerRevenir (ASX: REV) has achieved the first step in its proposed merger with British biotech company Bone with the raising of more than AUD$1.5 million in a share placement.
Genesis R&D subsidiary lays of half its staff
28 July, 2004 by Melissa TrudingerNew Zealand company Genesis R&D (NZX/ASX: GEN) has laid off more than half of the staff from its subsidiary AgriGenesis, due to a lack of success in raising capital for the spin-out company.
Up to his own devices: Alan Finkel on life after Axon
26 July, 2004 by Melissa TrudingerAsk Alan Finkel what he would do differently if he started another company, and he’s quick to reply. “I wouldn’t start another company overseas,” he says.
Amrad shareholders stock up
22 July, 2004 by Melissa TrudingerSome of Amrad's larger shareholders are boosting their holdings in the Melbourne company (ASX:AML), as long-time Japanese investor Chugai divests itself of its 10 per cent stake in the company.
